erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
.: "evidence for decreased calcitonin gene-related peptide (cgrp) receptors and compromised responsiveness to cgrp of fetoplacental vessels in preeclamptic pregnancies."..